Verona Pharma plc【VRNA】

時価総額

$728.1億

PER

呼吸器領域のバイオ医薬品の新興企業。主力治療薬Ohtuvayre（エンシフロトリン）の開発・販売を展開。2005年2月設立、2006年9月にRhinopharmaを買収、2017年4月にNASDAQ上場。従業員209名（2024年12月31日）、英国・米国中心に展開。

株価業績

サマリーテーブルに戻る

	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-65	-56	-69	-54	-173
Foreign exchange loss/(gain)	2	0	-4	2	-0
Amortization of debt issuance costs	0	0	0	0	1
Accretion of redemption premium on debt	0	0	0	0	0
Share-based compensation	22	25	14	19	41
Depreciation	1	1	1	1	1
Prepaid expenses	3	-1	-2	1	4
Tax incentive receivable	-1	7	-4	1	-5
Other current assets	-0	0	1	-1	0
Accounts payable	-1	10	-7	0	8
Accrued expenses	2	11	-9	-10	13
Operating lease liabilities	0	-0	-1	-1	-1
Income taxes	-	0	0	-1	10
Other current liabilities	0	-0	1	-1	2
Net cash used in operating activities	-45	-33	-60	-50	-122
Purchases of furniture and equipment	0	0	0	-	1
Net cash used in investing activities	10	-0	-0	-	-1
Proceeds from Issuance of Common Stock	200	1	150	57	97
Payment of offering costs in connection with the issuance of ordinary shares	13	-	10	-	-
Proceeds from Term Loans	5	-	10	10	123
Payment of debt issuance costs	0	-	0	0	7
Repayment of Term Loans	-	-	5	-	52
SVB Term Loan repayment costs	-	-	1	-	-
Payments of withholding taxes from share-based awards	-	7	5	5	15
Proceeds from Stock Options Exercised	0	-	1	2	5
Net cash provided by financing activities	192	-6	141	93	251
Effect of exchange rate changes on cash and cash equivalents	1	-0	-1	1	-0
Net change in cash and cash equivalents	158	-40	79	44	128
Income taxes paid	0	0	0	1	1
Interest paid	0	0	0	2	10
Loss on extinguishment of debt	-	-	-1	-	-4
Proceeds from (Repayments of) Other Long-Term Debt	-	-	-	29	-
Accretion Expense	-	-	-	-	9
Increase (Decrease) in Accounts Receivable	-	-	-	-	31
Increase (Decrease) in Inventories	-	-	-	-	8
Increase (Decrease) in License Agreement Obligations	-	-	-	-	1
Proceeds From Revenue Interest Purchase And Sale Agreement ("RIPSA”)	-	-	-	-	100